aadibio.com - Margin operasi WHWK

Logo korporat perusahaan Aadi Bio (WHWK)

The operating margin visualizes the core operational efficiency of Aadi Bioscience Inc (WHWK), while 0.00 shows the current value of this metric. The oncology base of targeted therapies retains all relevant patients following FDA approval. The patent for rare sarcoma therapy guarantees monopoly status and high profitability. Simultaneously, the company is implementing emission filtration systems, adhering to strict environmental standards.

WHWK: Rentabilitas kegiatan operasi Aadi Bio 20.03.2025 - 19.11.2026

WHWK (Aadi Bioscience, Inc.): rincian analitis lan laporan miturut indikator

Analisis komprehensif perusahaan:Aadi Bio, WHWK
Barang utama Aadi Bioscience

Operating margin determines the portion of revenue remaining after deducting all variable and fixed business operating costs, serving as a key indicator of cost management efficiency. An analysis of sales profitability based on operating profit allows for an assessment of the financial stability of Aadi Bioscience Inc (WHWK) within the context of the commercialization of Fyarro and the costs associated with expanding therapeutic indications for the treatment of oncological diseases.

Analisis pesaing

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|Margin dodolan operasi Accuray, Inc. ARAY|Rentabilitas operasi sellaslifesciences.com SLS|Tingkat bathi operasi ACTU|CTOR - Rentabilitas operasi|Rentabilitas kegiatan operasi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Rentabilitas operasi|FATE: Rasio bathi operasi|Margin dodolan operasi TCRX|Rentabilitas operasi CSBR|Margin operasi XBIT|Rentabilitas kegiatan operasi CEL-SCI Corp.|Rentabilitas operasi ostherapies.com OSTX|RADX: Rentabilitas dodolan miturut bathi operasi|ARTV: Margin dodolan operasi|ANL (Adlai Nortye) - Rentabilitas dodolan miturut bathi operasi|Veru (VERU) - Rentabilitas operasi|Margin dodolan operasi Tempest Therapeutics Inc|Rentabilitas operasi Xilio Therapeutics|Rentabilitas dodolan miturut bathi operasi RENB (Renovaro Inc.)|Rentabilitas operasi Mural Oncology PLC (MURA)|Margin operasi Kairos Pharma (KAPA)|Rentabilitas operasi onkuretherapeutics.com OKUR|GDTC: Rentabilitas dodolan miturut bathi operasi|CRIS: Margin dodolan operasi|apollomicsinc.com (APLM) - Margin dodolan operasi|THAR: Margin operasi|Margin dodolan operasi Advanced Biomed Inc.|Margin dodolan operasi GNPX|Rentabilitas dodolan miturut bathi operasi CLDI (Calidi Biotherapeutics)|Margin operasi SBFM|Xenetic Biosciences, Inc. - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Salarius Pharmaceuticals SLRX|Margin operasi purple-biotech.com PPBT|AONC - Rentabilitas operasi|BGNE: Rentabilitas operasi|CKPT: Margin operasi|Elevation Oncology - Tingkat bathi operasi|ICAD (iCAD) - Margin operasi|IKNA: Tingkat bathi operasi|Rentabilitas operasi Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Tingkat bathi operasi|Rentabilitas operasi MorphoSys Corporation MOR|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi